Related Experiment Video
Updated: Feb 19, 2026
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis
Hong-Bo Wang1, Xiao-Feng Liao, Jian Zhang
1Department of General Surgery, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, Hubei, China.
Background:
The treatment of patients with advanced gastric cancer remains a most challenging task in the clinical practice. Recently, targeted therapies have significantly impacted the treatment strategy for many common malignancies. The use of trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), plus chemotherapy proved to improve median overall survival in patients with advanced gastric cancer, compared with chemotherapy alone in Trastuzumab for Gastric Cancer (ToGA) trial. However, the prognostic value of HER2 status in gastric cancer remains controversial. Therefore, the aim of this study was to investigate the clinical pathology significance of HER2 overexpression in resectable gastric cancer for selecting the right patients with gastric cancer who may benefit from trastuzumab treatment.
Methods:
Publications reported the clinicopathological factors associated with HER2 status in gastric cancer from 2012 to 2017 were collected. The literature databases, such as "Cochrane Library", "Sciencedirect", "Springer", "PubMed", "Embase", were extensively searched to retrieve the clinical studies of HER2 expression in gastric cancer. The major outcomes measures were odds ratios (ORs) and their 95% CIs. Statistical analysis was carried out by Revman software 5.3. The Newcastle-Ottawa scale was used to assess the quality of evidence.
Result:
Fifteen studies met our inclusion criteria. This study demonstrated that the pooled OR for HER2 positivity was associated with being male (OR: 1.42; 95% CI: 1.23-1.64), well/moderately differentiated tumor (OR: 2.76; 95% CI: 1.72-4.45), and for intestinal-type tumor (OR: 0.31; 95% CI: 0.25-0.38). However, it had no correlation with depth of tumor (P = .07), venous invasion (P = .82), and lymphovascular invasion (P = .24).
Conclusion:
HER2-positive expression was associated with male gender, intestinal type, and well/moderate cell differentiation. We recommend that those gastric cancer patients who may benefit from trastuzumab treatment should be subjected to targeted therapies. However, detecting HER2 status may contribute to the target therapy for gastric carcinoma using trastuzumab. This would be strengthened by further studies incorporating comorbidity data, and outcomes from centralized programs.
Insights
HER2-positive gastric cancer is linked to male patients and specific tumor types. Identifying HER2 status is crucial for selecting patients who may benefit from trastuzumab targeted therapy.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Pathology
Background:
- Advanced gastric cancer treatment is challenging.
- Trastuzumab (HER2-targeted therapy) improves survival in advanced gastric cancer.
- The prognostic value of HER2 status in gastric cancer requires further clarification.
Purpose of the Study:
- To investigate the clinical pathology significance of HER2 overexpression in resectable gastric cancer.
- To identify patient subgroups who may benefit from trastuzumab treatment.
Main Methods:
- Systematic literature search (2012-2017) in Cochrane Library, Sciencedirect, Springer, PubMed, Embase.
- Meta-analysis of 15 studies using odds ratios (ORs) and 95% confidence intervals (CIs).
- Statistical analysis performed with Revman 5.3; study quality assessed using the Newcastle-Ottawa scale.
Main Results:
- HER2 positivity was associated with male gender (OR: 1.42) and well/moderately differentiated tumors (OR: 2.76).
- HER2 positivity was associated with intestinal-type tumors (OR: 0.31).
- No significant correlation was found between HER2 status and tumor depth, venous invasion, or lymphovascular invasion.
Conclusions:
- HER2-positive expression in gastric cancer correlates with male gender, intestinal type, and well/moderate cell differentiation.
- Detecting HER2 status is vital for guiding trastuzumab targeted therapy in gastric cancer.
- Further research incorporating comorbidity data and centralized program outcomes is recommended.
